Taho Pharmaceuticals Ltd. (TPEX:6467)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
106.00
-6.50 (-5.78%)
At close: Jul 28, 2026
Market Cap5.50B +57.6%
Revenue (ttm)5.42M +80.8%
Net Income-232.53M
EPS-4.49
Shares Out 52.37M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume301,529
Open112.00
Previous Close112.50
Day's Range104.50 - 113.00
52-Week Range61.50 - 208.50
Beta-32.00
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Taho Pharmaceuticals

Taho Pharmaceuticals Ltd., a commercial-stage pharmaceutical company, focuses on the development of drug delivery systems in transdermal and transmucosal systems in Taiwan. The company offers TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Its pipeline includes TAH3311 Apixaban oral film, which is in phase III; TAH3341, an anticoagulant apixaban ODF extended-release film, which is in preclinical stage. The company also develops TAH2211 Buprenorphine/Naloxone ... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Employees 35
Stock Exchange Taipei Exchange
Ticker Symbol 6467
Full Company Profile

Financial Performance

Financial Statements